NewAmsterdam Pharma Company N.V. (NAMS)
Nasdaq: NAMS · Pharmaceutical Preparations · Narrden, NL · filing with the SEC since 2022
Income statement, as filed
In thousands of US dollars (USD), as filed; per-share figures in US dollars; share counts. The fiscal year ends in December.| Fiscal year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Period ending | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 |
| Report filed | Feb 18, 2026 | Feb 26, 2025 | Feb 28, 2024 | Mar 31, 2023 | · |
| Revenue | 22,503 | 45,563 | 14,090 | 102,694 | · |
| Research and development | 141,832 | 151,406 | 159,424 | 86,744 | 28,974 |
| Selling, general and administrative | 106,354 | 70,446 | 37,633 | 19,507 | 6,003 |
| General and administrative | 15,374 | 14,438 | 16,323 | 13,594 | · |
| Total operating expenses | 248,186 | 221,852 | 197,057 | 106,251 | 34,977 |
| Operating income | -225,683 | -176,289 | -182,967 | -3,557 | -34,977 |
| Interest expense | · | · | · | 287 | 411 |
| Interest and investment income | 27,592 | 16,881 | 11,283 | · | · |
| Income before income taxes | -203,819 | -241,599 | -176,910 | -22,634 | -41,785 |
| Income tax expense | · | -1 | 27 | · | · |
| Net income including non-controlling interests | -203,819 | -241,598 | -176,937 | -22,634 | -41,785 |
| Net income | -203,819 | -241,598 | -176,937 | -22,634 | -41,785 |
| Earnings per share, basic | -1.72 | -2.56 | -2.15 | -1.19 | -3.81 |
| Earnings per share, diluted | -1.72 | -2.56 | -2.15 | -1.19 | -3.81 |
| Weighted average shares, basic | 118,424,231 | 94,358,067 | 82,161,956 | 18,966,235 | 10,978,874 |
| Weighted average shares, diluted | 118,424,231 | 94,358,067 | 82,161,956 | 18,966,235 | 10,978,874 |
As filed with the SEC, each figure from the newest report that carries it, and linked to it. Nothing here is computed.A dot is a line not tagged for that period. r restated by the company in a later report; b a share figure put on the newest basis or filed in the wrong unit. Hover a figure for its filing and note.
What each line is, and the XBRL concept behind it
Revenue what customers paid for what it sold
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTaxResearch and development spent on inventing what it sells next
us-gaap:ResearchAndDevelopmentExpenseSelling, general and administrative the cost of selling and of running the company
us-gaap:SellingGeneralAndAdministrativeExpenseGeneral and administrative the cost of running the company itself
us-gaap:GeneralAndAdministrativeExpenseTotal operating expenses the running costs together
us-gaap:OperatingExpensesOperating income profit from running the business, before interest and tax
us-gaap:OperatingIncomeLossInterest expense what its borrowing cost
us-gaap:InterestExpenseInterest and investment income what its cash and investments earned
us-gaap:InvestmentIncomeInterestIncome before income taxes profit before tax
us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterestIncome tax expense tax charged on the period's profit
us-gaap:IncomeTaxExpenseBenefitNet income including non-controlling interests the whole group's profit, minority holders' share included
us-gaap:ProfitLossNet income the profit or loss that belongs to the company's shareholders
us-gaap:NetIncomeLossEarnings per share, basic net income per share outstanding
us-gaap:EarningsPerShareBasicEarnings per share, diluted net income per share, counting every share that could be issued
us-gaap:EarningsPerShareDilutedWeighted average shares, basic the average count of shares outstanding
us-gaap:WeightedAverageNumberOfSharesOutstandingBasicWeighted average shares, diluted the average count with every share that could be issued
us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding